Premium
High‐dose cytosine arabinoside and mitoxantrone in previously‐treated acute leukemia patients
Author(s) -
Lejeune C.,
Tubia.,
Gastaut J. A.,
Maraninchi D.,
Richard B.,
Launay M. C.,
Sainty D.,
Sebahoun G.,
Carcassonne Y.
Publication year - 1990
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1990.tb00386.x
Subject(s) - mitoxantrone , medicine , refractory (planetary science) , acute myeloblastic leukemia , leukemia , acute leukemia , gastroenterology , cytarabine , chemotherapy , regimen , oncology , physics , astrobiology
35 patients with refractory or relapsed acute leukemia received salvage chemotherapy using high‐dose cytosine arabinoside 2 g/m 2 intravenously for 3 hours every 12 h, in 8 doses, followed by continuous infusion of mitoxantrone 12 mg/m 2 /day for 2 d. 9 patients had acute myeloblastic leukemia (AML), (4 relapsed, 5 refractory), 20 had acute lymphoblastic leukemia (ALL) (11 relapsed, 9 refractory) and 6 had chronic myelogenous leukemia (CML) in the blastic phase (BP). 4 out of 9 AML and 16 out of 20 ALL achieved complete remission. Median survival was 6 months for all patients and 10 months for responders. A short (1.5 months) chronic phase was achieved in 3 patients with CML. The main toxic effect was hematologic. A pharmacokinetic study was performed on mitoxantrone. No correlation was found with clinical response. The combination of mitoxantrone and ara‐C is an effective antileukemic regimen, especially in ALL.